Healthcare

Neurizon Therapeutics Limited (ASX:NUZ) has received written feedback from the US Food and Drug Administration following a Type C meeting request regarding NUZ-001, its investigational treatment for amyotrophic lateral sclerosis (ALS). The feedback provides guidance on the regulatory pathway and clinical development strategy.

This article summarises those details, the sector context, the risks the company identifies and the next steps indicated.

This article summarises the contents of that announcement, sets out the surrounding sector backdrop, notes risks that the company itself flags, and outlines the next steps described in the release.

The transaction gives CSL access to a clinical-stage asset targeting conditions where treatmentOptionsremain limited, while also placing responsibility for specified clinical development activities with the Australian healthcare group.

Mavrox provides the initial US direct-to-consumer telehealth route for ROXUS, and Strive Pharmacy supports compounding and fulfilment. The company states that Strive has set up the operational systems needed to receive, compound and fulfil valid patient-specific ROXUS prescriptions. ROXUS is LTR Pharma's intranasal medication …

Estimated revenue for the September quarter was US$1,028K, up 38% on the June quarter figure of US$745K, and up 24% excluding a US$105K one-off item. Fee-for-serviceMedicarerevenue was estimated at US$743K, up 32%, with September alone estimated at US$284K. The company stresses that, from April …

Vitasora Health Limited (ASX:VHL) is a connected-care company serving the US healthcare market through technology-enabled remote patient monitoring and chronic care management services. Its October 2026 update focused on September-quarter revenue estimates, patient enrolment, care-coordinator productivity and the operating capacity supporting its US care …